Explore the Agenda
8:00 am Check In & Morning Coffee
9:00 am Chair’s Opening Remarks
Envisioning the Success of Peptide-Based Therapeutics Enabled by Robust Biopharma Partnerships, Investments & Innovation Strategies
9:15 am Business Development & Investment Panel Discussion — Exploring the Future of Peptide-Therapeutics Through Successful Funding Rounds, Biopharmaceutical Partnerships & Collaborations
The biopharmaceutical sector continues to innovate peptide discovery innovations, from new macrocycles to new delivery methods and are thriving on strategic alliances, which allow for cross-functional sharing of knowledge, and experience to advance peptide drugs to patients faster. Hear first-hand how investors and key biotechs are keeping up with the peptide momentum through investments, alliances and collaborations.
Key questions to be addressed include:
- How to strategize the complexities, risks and decision-making strategies for choosing the right platform to invest and advance innovative approaches in the peptide industry?
- What are the key areas and spaces that peptides can fill in the biotechnology sector?
- What does it take for a small biotech to survive and get noticed from an investor or big pharma?
9:45 am The Peptide IP Landscape: Winning with Knowledge, Strategy & Innovation from Peptide Discovery to Development
- Harnessing critical understanding of regulatory and IP implications from drug discovery to formulation to ensure smooth market access for your peptide therapeutic
- Outlining the key IP bottlenecks for making changes to peptide drugs
- Defining the data packages required to be sufficient for IP submissions
10:15 am Morning Break & Networking
Track A: Drug Discovery
Trailblazing the Next Wave of Peptide Design Through Physics & De Novo Approaches Towards Next Generation Peptide Therapeutic Modalities
10:50 am From Traditional Peptide Discovery to Physics-Based AI Design – A Case Study of GLP-1 & β-Catenin Programs
- Showcasing a traditional drug discovery case study with example of GLP-1 class drugs highlighting the challenges with these approaches
- Demonstrating the application of AI/ML and physics-based tools to design novel peptide binders with drug-like properties, enabling multi-objective optimization toward a potential clinical candidate
- Presenting a case of current β-catenin project using physics-based AI approaches
11:20 am Discovery & Characterization of a Selective, Pure Antagonist of TNFR1
- Introducing de novo designed miniproteins as a next generation therapeutic modality
- Highlighting the application to antagonism of TNFR1
- Showcasing differentiation against existing therapies
Track B: Formulation & CMC
Harnessing Carrier Systems & Peptides as Drug Delivery Vehicles to Enable Laser- Focused Targeting of Peptide Drug Delivery
10:50 am Unlocking a Peptide-Based Platform for Targeted Delivery of Therapeutic Agents
- Rationally designing and optimizing AI-driven peptide-vectors for targeted delivery of different payloads including peptide, protein and RNA
- Demonstrating safety and characterization of peptide-based nanoparticles for extrahepatic delivery of RNA
- Leveraging a peptide-based nanoparticle platform for systemic targeted delivery of therapeutic mRNA: T cell engineering and tumor selectivity
NEW COMPANY
11:20 am Revolutionizing Intracellular Delivery with an Advanced Peptide-Based Platform for Clinical Success
- Pioneering endosomal escape through rationally designed peptide shuttles, enabling efficient delivery of small molecules, proteins, enzymes and oligonucleotides across diverse cell types
- Delivering functional biomolecules in different animal models
- Demonstrating clinical potential of the Feldan technology through in vivo data and progression to first-in-human trial for basal cell carcinoma
NEW COMPANY
11:50 am From Molecule to Market: An Integrated CRDMO Approach for Peptides & Oligonucleotides
- Peptide and oligonucleotide therapeutics increasingly present challenges related to molecular complexity, developability, and global regulatory expectations
- Describing an end-to-end CRDMO approach, supporting programs from early discovery and research through CMC development, process scale-up, GMP manufacturing, and commercial supply.
- Drawing on Hybio’s practical global experience across the full development lifecycle, the talk will highlight how early technical and developability considerations can be integrated with downstream manufacturing strategies to enable robust, scalable, and compliant production of complex peptide therapeutics, while de-risking development timelines and supporting successful global commercialization
12:00 pm Lunch Break & Networking
Track A: Drug Discovery
Leveraging Case Study Examples of Peptide Discoveries to Achieving High Potency & Selectivity of Peptide-Based Therapeutics & Vaccines
1:00 pm Non-Degradative Macrocyclic Molecular Glue DELs
- RapaGlues are non-degrading molecular glues that recruit FKBP12 to form a new PPI ternary complex, successfully
- addressing the large portion of the undrugged cytosolic and transmembrane proteome
- Leveraging the RapaGlue Platform’s proprietary DELs (over 8 billion compounds) and AI/ML-powered predictions for modelling-guided design to explore the topological diversity required to expand the range of targets
- RapaGlues promote the intracellular assembly of a proteinsized (+12kD) inhibitor, achieving a high success rate against multiple hard-to-drug targets with high potency, selectivity, and cell permeability
NEW DATA
1:30 pm Active Immunotherapy Using Universal Epitopes
- Peptide vaccine technology involves prolonged suppression due to the production of anti-endogenous target protein antibody
- Peptide vaccines consist of highly immunogenic helper T cell epitope (AJP001) and B cell epitope originated from target protein
- Sharing the usefulness of antibody-inducing peptides based on non-clinical and clinical trial data of developed compounds
NEW COMPANY
Track B: Formulation & CMC
Overcoming Bioanalytical & CMC Challenges in Analyzing & Effectively Scaling Peptides to Meet Clinical & Regulatory Expectations
1:00 pm Developing a Fit for Purpose Bioanalytical Strategy to Analyze a Cell-Penetrating Peptide: From Protein Precipitation to Solid Phase Extraction to Affinity Capture
- Introducing the properties of cell penetrating peptides
- Discussing the challenges of bioanalysis
- Utilizing a fit for purpose bioanalytical strategy: from protein precipitation to solid phase extraction to affinity capture
1:30 pm Using the XeriSol Formulation Platform for Peptide Parenteral Drug Delivery
- Presenting a non-aqueous, high concentration subcutaneous solution
- Enabling room temperature stability
- Showcasing excellent safety and toxicity profiles
NEW COMPANY
2:00 pm Afternoon Break & Networking
Unravelling the Challenges to Effectively Design & Formulate Peptide Therapies with Effective Analytics & Pharmacology
2:30 pm PepTalk – Deep-Dive Audience Discussion Take a seat in one of the discussion sessions below and immerse yourself into an engaging discussion with thought-leading peptide pharma experts and your peers.
Practical Approaches to Characterize ADME & Design Translatable In Vitro & In Vivo PK/PD Studies with Jianzhong Wen
- What in vitro stability assays do you rely on early to triage candidates, and which have predicted in vivo best for your programs?
- Which permeability assays or systems have been most predictive for peptides in your experience?
- How much is needed to evaluate metabolism or transporter related DDI for peptide drugs?
Improving Permeating Agent Performance to Achieve Successful Peptide Oral Bioavailability with Shelley Allen
- How to use non-naturals to improve stability against proteases and other micro-environment challenges?
- How can we use half-life extension lipidation for permeating agents to improve bioavailability?
- What tissue properties or targets are important to consider for improved bioavailability?
3:15 pm Peptide Inhibitor of Pan Corona Virus Fusion Protein
- Introducing of the Pan-Cov peptide inhibitor program and showcasing the peptide modality strategy
- Establishing in vitro and ex vivo efficacy assays for peptide optimization
- Discussing the challenges associated with peptide PK and biodistribution
NEW DATA